Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Journal article published in 2020 by
Lorenzo D’Ambrosio 
,
Nathan Touati,
Jean‐Yves-Y. Blay,
Giovanni Grignani ,
Ronan Flippot,
Anna M. Czarnecka,
Sophie Piperno‐Neumann,
Javier Martin‐Broto,
Roberta Sanfilippo,
Daniela Katz,
Florence Duffaud,
Bruno Vincenzi,
Daniel P. Stark,
Filomena Mazzeo,
Armin Tuchscherer
and other authors.
,
Nathan Touati,
Jean‐Yves-Y. Blay,
Giovanni Grignani ,
Ronan Flippot,
Anna M. Czarnecka,
Sophie Piperno‐Neumann,
Javier Martin‐Broto,
Roberta Sanfilippo,
Daniela Katz,
Florence Duffaud,
Bruno Vincenzi,
Daniel P. Stark,
Filomena Mazzeo,
Armin Tuchscherer
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 